文献速递腹部介入USCTMR

SonoVue与Sonazoid在超声造影-CT/MRI融合成像引导射频消融显示不清肝脏恶性肿瘤中的比较研究:前瞻性个体内分析

A Comparative Study of SonoVue and Sonazoid for Contrast-Enhanced Ultrasound CT/MRI Fusion Guidance During Radiofrequency Ablation of Poorly Visualized Hepatic Malignancies: A Prospective Intra-Individual Analysis.
PubMed 文献 · Ultrasound Med Biol · 2024-09-20

前瞻性个体内研究纳入23例B超显示不清的肝脏恶性肿瘤(≤3 cm)患者,同日先后使用SonoVue和Sonazoid进行超声造影-CT/MRI融合成像引导射频消融。两种造影剂在相应时相的肿瘤可见度评分相当,但Sonazoid的Kupffer期评分优于SonoVue的晚期血管相;放射科医生更倾向于使用Sonazoid融合成像引导射频消融。

要点

  • 对B超显示不清的≤3 cm肝脏恶性肿瘤,超声造影-CT/MRI融合成像可显著改善肿瘤可见度。
  • Sonazoid融合成像的Kupffer期可见度评分(3.70±0.56)优于SonoVue融合成像的晚期血管相(2.96±0.88)。
  • 放射科医生更偏好Sonazoid融合成像引导射频消融,观察者间一致性中等(Kappa=0.587)。

核心结论

  • 使用SonoVue或Sonazoid的超声造影-CT/MRI融合成像均能大幅改善B超显示不清肿瘤在超声-CT/MRI融合成像中的可见度,但放射科医生更倾向于使用Sonazoid而非SonoVue来引导射频消融操作。

研究设计与样本

  • 前瞻性个体内比较研究,纳入23例B超显示不清的肝脏恶性肿瘤(≤3 cm)患者,同日先后使用SonoVue和Sonazoid(间隔至少15分钟)进行实时超声造影-CT/MRI融合成像,评估肿瘤可见度和放射科医生偏好。

诊断标准与关键数值

  • 肿瘤可见度和放射科医生偏好采用4分制评分,在SonoVue融合成像和Sonazoid融合成像的动态期及Sonazoid融合成像的Kupffer期进行评估;Kupffer期评分3.70±0.56 vs 晚期血管相2.96±0.88,p=0.002;观察者间一致性Kappa值=0.587(95%CI 0.403-0.772)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: This study aimed to evaluate the effectiveness of two contrast agents, SonoVue (SV) and Sonazoid (SZ), by comparing them intra-individually in contrast-enhanced ultrasound (CEUS)-CT/MRI fusion imaging (FI) to improve the visibility of inconspicuous liver malignancies on B-mode sonography for guiding percutaneous radiofrequency ablation (RFA). Additionally, the radiologists' preference between SonoVue- CT/MRI FI (SV-FI) and Sonazoid-CT/MRI FI (SZ-FI) was determined.

METHODS: This prospective study enrolled 23 patients with inconspicuous hepatic malignancies (≤ 3 cm) on B-mode US who underwent both SV-FI and SZ-FI for RFA guidance. The patients underwent real-time CEUS FI with CT/MRI on the same day, utilizing both SV and SZ with at least 15-min intervals. Tumor visibility and radiologists' preferences were assessed and graded using a 4-point scale during the dynamic phases of both SV-FI and SZ-FI and the Kupffer phase of SZ-FI.

RESULTS: The tumor visibility scores obtained from CEUS-CT/MRI FI were significantly better than those obtained from US-FI. Indeed, SV-FI and SZ-FI demonstrated comparable visibility scores when corresponding phases were compared (p > 0.05). However, the Kupffer phase images of SZ-FI displayed superior visibility scores (3.70 ± 0.56 vs. 2.96 ± 0.88; p = 0.002) than the late vascular phase images of SV-FI. The radiologists favored SZ-FI in many cases, exhibiting moderate inter-observer agreement (Kappa value = 0.587; 95% CI, 0.403-0.772).

CONCLUSION: Although CEUS-CT/MRI FI with either SV or SZ substantially improved the visibility of inconspicuous tumors on US-CT/MRI FI, radiologists preferred SZ to SV to guide the RFA procedure.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Kim H, Kim JH, Lee JM, et al. A Comparative Study of SonoVue and Sonazoid for Contrast-Enhanced Ultrasound CT/MRI Fusion Guidance During Radiofrequency Ablation of Poorly Visualized Hepatic Malignancies: A Prospective Intra-Individual Analysis. Ultrasound Med Biol. 2024. PMID: 39306481. doi:10.1016/j.ultrasmedbio.2024.08.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。